|
Index | - | P/E | - | EPS (ttm) | -11.14 | Insider Own | 1.10% | Shs Outstand | 7.17M | Perf Week | -6.81% |
Market Cap | 21.64M | Forward P/E | - | EPS next Y | -4.16 | Insider Trans | - | Shs Float | 5.70M | Perf Month | -43.26% |
Income | -31.40M | PEG | - | EPS next Q | -0.92 | Inst Own | 31.90% | Short Float | 4.06% | Perf Quarter | -44.42% |
Sales | - | P/S | - | EPS this Y | 74.20% | Inst Trans | -7.40% | Short Ratio | 0.70 | Perf Half Y | -62.50% |
Book/sh | 4.10 | P/B | 0.53 | EPS next Y | -7.60% | ROA | -44.50% | Target Price | 22.50 | Perf Year | -83.61% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | -80.00% | 52W Range | 2.00 - 41.00 | Perf YTD | -58.52% |
Dividend | - | P/FCF | - | EPS past 5Y | 58.10% | ROI | - | 52W High | -94.66% | Beta | 0.47 |
Dividend % | - | Quick Ratio | 3.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 9.50% | ATR | 0.33 |
Employees | 17 | Current Ratio | 3.00 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 38.86 | Volatility | 13.43% 12.29% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 81.80% | Profit Margin | - | Rel Volume | 0.04 | Prev Close | 2.29 |
Shortable | Yes | LT Debt/Eq | 0.51 | Earnings | Mar 29 AMC | Payout | - | Avg Volume | 330.21K | Price | 2.19 |
Recom | 1.70 | SMA20 | -14.10% | SMA50 | -24.92% | SMA200 | -66.23% | Volume | 13,204 | Change | -4.37% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite